Induction of Hyperandrogenism in Lean Reproductive-Age Women Stimulates Proatherogenic Inflammation

Abstract

We determined the effect of hyperandrogenemia as observed in polycystic ovary syndrome (PCOS) on fasting and glucose-stimulated proatherogenic inflammation markers in lean healthy reproductive-age women. Sixteen lean healthy ovulatory reproductive-age women were treated with 130 mg of DHEA or placebo (n=8 each) for 5 days. Interleukin-6 (IL-6) mRNA and IL-6 release from mononuclear cells (MNC), plasma IL-6 and C-reactive protein (CRP), and MNC-derived (matrix metalloproteinase-2) MMP-2 protein were quantified in the fasting state and 2 h after glucose ingestion, before and after treatment. Before treatment, subjects receiving dehydroepinadrosterone (DHEA) or placebo exhibited no differences in androgens, or any proatherogenic inflammation markers while fasting and after glucose ingestion. Compared with placebo, DHEA administration raised levels of testosterone, androstenedione, and DHEA-sulfate (DHEA-S), and increased the percent change from baseline in fasting IL-6 mRNA, IL-6 release, plasma IL-6, and CRP and MMP-2 protein. However, there were no differences in any of the proatherogenic inflammation markers following glucose ingestion after DHEA administration. We conclude that in lean reproductive-age women, proatherogenic inflammation in the fasting state increases after raising circulating androgens to levels observed in PCOS. However, this hyperandrogenemia-induced MNC activation does not provoke a similar response to subsequent glucose ingestion.

Key words

atherogenesis - inflammation - hyperglycemia

• References

• 1 Knochenhauer ES, Key TJ, Kahser-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern Unites States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082
• 2 Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Relative prevalence of different androgen excess disorders in 950 women refereed because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006; 91: 2-6
• 3 Goodarzi MO, Korenman SG. The importance of insulin resistance in polycystic ovary syndrome. Fertil Steril 2002; 77: 255-258
• 4 Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human theca cells from women with polycystic ovary syndrome by activating its own receptor and using inositoglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 83: 2001-2005
• 5 Freeman MS, Mansfield MW, Barrett JH, Grant PJ. Insulin resistance: an atherothrombotic syndrome. Thromb Haemost 2003; 89: 161-168
• 6 Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103: 1410-1445
• 7 Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 89. 5454-5461
• 8 González F, Rote NS, Minium J, Kirwan JP. Hyperglycemia alters tumor necrosis factor-α release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 5336-5342
• 9 González F, Rote NS, Minium J, Kirwan JP. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-α release in obese women with polycystic ovary syndrome. J Endocrinol 2006; 188: 521-529
• 10 González F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 336-340
• 11 González F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor κB triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1508-1512
• 12 González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism 2009; 58: 954-962
• 13 González F, Rote NS, Minium J, Kirwan JP. Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. Cytokine 2010; 51: 240-244
• 14 Barnes PJ, Karin M. Nuclear factor-κB: pivitol transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-1071
• 15 Moshage HJ, Roelofs HM, van Pelt JF, Hazenberg BP, van Leeuwen MA, Limburg PC, Aarden LA, Yap SH. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988; 155: 112-117
• 16 Radler-Pohl A, Gebel S, Sachsenmaier C, König H, Krämer M, Oehler T, Streile M, Ponta H, Rapp U, Rahmsdorf HJ, Cato ACB, Angel P, Herlich P. The activation and activity control of AP-1 (Fos/Jun). Ann N Y Acad Sci 1993; 684: 127-148
• 17 Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively express matrixdegrading proteases. Proc Natl Acad Sci USA 1995; 92: 402-406
• 18 Southgate KM, Davies M, Booth RFG, Newby AC. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J 1992; 288: 93-99
• 19 Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001; 103: 1194-1197
• 20 Newby AC. Dual role of matrix metalloproteases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Res 2005; 85: 1-31
• 21 González F, Nair KS, Daniels JK, Basal E, Schimke JM. Hyperandrogenism sensitizes mononuclear to promote glucose-induced inflammation in lean reproductive-age women. Am J Physiol Endocrinol Metab 2012; 302: E297-E306
• 22 González F, Rote NS, Minium J, Kirwan JP. Insulin sensitivity and hyperandrogenism in polycystic ovary syndrome are related to proatherogenic inflammation in the fasting state. Reprod Sci 2009; 16 (2 Suppl) 82A
• 23 González F, Kirwan JP, Rote NS, Minium J. Glucose ingestion stimulates atherothrombotic inflammation in polycystic ovary syndrome. Am J Physiol Endocrinol Metab 2013; 304: E375-E383
• 24 Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
• 25 Aljada A, Ghanim H, Dandona P. Translocation of p47phox and activation of NADPH oxidase in mononuclear cells. Methods Molec Biol 2002; 196: 99-103
• 26 Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564-1571
• 27 Ashcroft GS, Mills SL. Androgen receptor-mediated inhibition of cutaneous wound healing. J Clin Invest 2002; 110: 615-624
• 28 Ripple MO, Henry WF, Schwarze SR, Wilding W, Weindruch R. Effects of anti-oxidants on androgen-induced AP-1 and NF-κB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1991; 14: 1227-1232
• 29 González F, Daniels JK, Bearson DM, Blair HE. Hyperandrogenism induces a proinflammatory TNFα response to glucose ingestion in a receptor-dependent fashion. J Clin Endocrinol Metab 2014; 99: E848-E854
• 30 De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor kappaB. Oncogene 2006; 25: 6868-6886
• 31 Rao NA, McCalman MT, Moulos P, Francoijs KJ, Chatziioannou A, Kolisis FN, Alexis MN, Mitsiou DJ, Stunnenberg HG. Coactivation of GR and NFKB alters the repertoire of their binding sites and target genes. Genome Res 2011; 21: 1404-1416
• 32 Cinar B, Yeung F, Konaka H, Mayo MW, Freeman MR, Zhau HE, Chung LW. Identification of a negative regulatory cis-element in the enhancer core region of the prostate-specific antigen promoter: implications for intersection of androgen receptor and nuclear factor-kappaB signalling in prostate cancer cells. Biochem J 2004; 379: 421-431
• 33 Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schütz G. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998; 93: 531-541
• 34 Ogawa S, Lozach J, Jepsen K, Sawka-Verhelle D, Perissi V, Sasik R, Rose DW, Johnson RS, Rosenfeld MG, Glass CK. A nuclear receptor corepressor transcriptional checkpoint controlling activator protein 1-dependent gene networks required for macrophage activation. Proc Natl Acad Sci USA 2004; 101: 14461-14466
• 35 Kimura M, Tanaka S, Yamada Y, Kiuchi Y, Tamakawa T, Sekihara H. Dehydroepiandrosterone decreases tumor necrosis factor-α and restores insulin sensitivity: independent effect from secondary weight reduction in genetically obese zucker fatty rats. Endocrinol 1998; 139: 3249-3253
• 36 Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Kawasaki S, Okamura A, Sehihara H. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phospatase and fructose-1,6-biphosphatase activities in C57BL/Ksj-db/db mice. Diabetes 1999; 48: 1579-1585
• 37 Barkhausen T, Hildebrand F, Krettek C, van Griensven M. DHEA-dependent and organ-specific regulation of TNF-α mRNA expression in a murine polymicrobial sepsis and trauma model. Critical Care 2009; 13: R114